![Manfred Mosk](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Manfred Mosk
Keine laufenden Positionen mehr
Karriereverlauf von Manfred Mosk
Ehemalige bekannte Positionen von Manfred Mosk
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Cordex Pharma, Inc.
![]() Cordex Pharma, Inc. Medical SpecialtiesHealth Technology Cordex Pharma, Inc. is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine 5'-triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex Pharma was founded on February 9, 1996 and is headquartered in Philadelphia, PA. | Vorsitzender | - | 07.12.2005 |
EOM PHARMACEUTICALS HOLDINGS, INC. | Direktor/Vorstandsmitglied | - | - |
Statistik
International
Vereinigte Staaten | 3 |
Operativ
Chairman | 1 |
Director/Board Member | 1 |
Sektoral
Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Cordex Pharma, Inc.
![]() Cordex Pharma, Inc. Medical SpecialtiesHealth Technology Cordex Pharma, Inc. is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine 5'-triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex Pharma was founded on February 9, 1996 and is headquartered in Philadelphia, PA. | Health Technology |
ImmunoCellular Therapeutics Ltd.
![]() ImmunoCellular Therapeutics Ltd. BiotechnologyHealth Technology ImmunoCellular Therapeutics, Ltd. is a clinical-stage pharmaceutical company, focused on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. The company was founded on March 20, 1987 and is headquartered in Montvale, NJ. | Health Technology |
- Börse
- Insiders
- Manfred Mosk
- Erfahrung